Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Cardiovascular Outcomes In patients with established cardiovascular disease and obesity, but without diabetes, semaglutide reduced major adverse cardiovascular events by 20 percent
Weight loss was never the aim, but it emerged as a common side effect of semaglutide
Consequently, the extension phase of both trials was discontinued
/https%3A%2F%2Fopengraph.b-cdn.net%2Fproduction%2Fimages%2F2ed46913-f157-43c3-9418-19fea49af16c.png%3Ftoken%3DUl4O1QAtXTaMUjOfpBooUL-C8jajM-YwYFPrjCtr6ms%26height%3D1080%26width%3D1080%26expires%3D33315971423/og.png)
Tirzepatide itself, being injected, is not affected by oral fiber intake
Risk may increase when: Intake declines GI symptoms persist Dietary diversity narrows Evidence strength: Moderate plausibility
US$ 27.47
US$ 23.79
US$ 20.98
US$ 25.23
US$ 29.73
US$ 26.79
US$ 20.97
US$ 20.07
US$ 20.93
